Autobio Diagnostics (603658) Stock Overview

Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products. It develops immunoassay, biochemistry, and microbiology products, as well as reagents; and instruments, as well as medical laboratory solutions. The company's immunoassay products AutoLumo A1860 that provides user experience for small and medium size labs; an automated chemiluminescence immunoassay analyzer; AutoLumo A2000 Plus, an automatic chemiluminescence immunoassay analyzer; AutoLumo A1000, an automated chemiluminescence immunoassay analyzer; and LUmo microplate luminometers, PHOmo microplate readers, and iWO and iWO-960 microplate washers. Its microbiology products BC60, an automatic blood culture instrument; MALDI-TOF MS system for the identification of pathogenic bacteria; AutoMic-I60 for microbial identification and antibiotic susceptibility testing; BC120, an automated blood culture system; and AutoMimo 1200, an instrument for improving pipetting efficiency and optimize workflow in the lab. The company also offers blood culture bottles, AST cards, mycoplasma TIES, and AUTOF MS reagents; AutoMolec 1600, an integrated and automated molecular diagnostics analyzer; and AutoMolec 3000, an in vitro molecular detection instrument. In addition, it engages in biological research and development; and the provision of technical and support services. The company was formerly known as Lifeclone Diagnostics Co., Ltd. and changed its name to Autobio Diagnostics Co., Ltd. in 2003. Autobio Diagnostics Co., Ltd. was founded in 1998 and is headquartered in Zhengzhou, China. Autobio Diagnostics Co., Ltd. operates as a subsidiary of Zhengzhou Autobio Co., Ltd.